...

首页> 外文期刊>European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) >First-in-human phase I trial of the anti-CEACAM5 antibody-drug conjugate SAR408701 in patients with advanced solid tumors (NCT02187848)

【24h】

First-in-human phase I trial of the anti-CEACAM5 antibody-drug conjugate SAR408701 in patients with advanced solid tumors (NCT02187848)

机译：抗CEACAM5抗体-药物偶联物SAR408701在晚期实体瘤患者中的首次人体I期试验（NCT02187848）

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)》 |2016年第null期|共2页
作者
Gazzah A.; Stjepanovic N.; Ryu M. H.; Tabernero J.; Soria J. C.; Bedard P.; Kang Y. K.; Bahleda R.; Guillemin-Paveau H.; Henry C.; Hatteville L.; Zilocchi C.; Demers B.; Hierro C.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. First-in-human phase I trial of the anti-CEACAM5 antibody-drug conjugate SAR408701 in patients with advanced solid tumors (NCT02187848) [J] . Gazzah A., Stjepanovic N., Ryu M. H., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2016,第Null期

机译：抗CEACAM5抗体-药物偶联物SAR408701在晚期实体瘤患者中的首次人体I期试验（NCT02187848）
2. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors (vol 36, pg 3298, 2018) [J] . Strickler J. H., Weekes C. D., Nemunaitis J. Journal of Clinical Oncology . 2019,第3期

机译：患有先进实体瘤的患者的靶向C-MET的抗体 - 药物缀合物的抗体 - 药物缀合物的抗体 - 药物缀合物的第一阶段I，剂量 - 升级和延伸研究（Vol 36，PG 3298,2018）
3. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors [J] . Strickler John H., Weekes Colin D., Nemunaitis John, Journal of Clinical Oncology . 2018,第33期

机译：患有先进实体肿瘤的患者的靶向C-Met的抗体 - 药物缀合物的抗体 - 药物缀合物的一阶段I，剂量升级和延伸研究。
4. Phase I Clinical Trial with Her-2 B-Cell Chimeric and MultiEpitope Based Peptide Vaccines in Patients with Metastatic and/or Recurrent Solid Tumors [C] . Pravin T.P. Kaumaya, Kevin Chu Foy, Joan Garrett American Peptide Symposium . 2009

机译：患者临床试验与患有转移和/或复发性固体瘤的患者的HER-2 B细胞嵌合和多型肽疫苗
5. A New Hybrid Agent-Based Model to Evaluate Antibody-Drug Conjugates in Solid Tumors [D] . Menezes, Bruna. 2021

机译：基于杂种代理的基于模型，以评估固体瘤中的抗体 - 药物缀合物
6. First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate PF-06263507 in patients with advanced solid tumors [O] . Geoffrey I. Shapiro, Ulka N. Vaishampayan, Patricia LoRusso, -1

机译：抗5T4抗体-单甲基auristatin偶联物PF-06263507在晚期实体瘤患者中的首次人类试验
7. First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors [O] . Geoffrey I. Shapiro, Ulka N. Vaishampayan, Patricia LoRusso, 2017

机译：抗5T4抗体-单甲基auristatin偶联物PF-06263507在晚期实体瘤患者中的首次人类试验

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号